G A Piazza
Overview
Explore the profile of G A Piazza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1001
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li N, Lee K, Xi Y, Zhu B, Gary B, Ramirez-Alcantara V, et al.
Oncogene
. 2014 Apr;
34(12):1499-509.
PMID: 24704829
The cyclic nucleotide phosphodiesterase 10A (PDE10) has been mostly studied as a therapeutic target for certain psychiatric and neurological conditions, although a potential role in tumorigenesis has not been reported....
2.
White M, Johnson G, Zhang W, Hobrath J, Piazza G, Grimaldi M
J Neurosci Res
. 2013 Jan;
91(3):393-406.
PMID: 23280445
Malignant gliomas have low survival expectations regardless of current treatments. Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent cell transformation and slow cancer cell growth by mechanisms independent of cyclooxygenase (COX) inhibition. Certain...
3.
Arora S, Singh S, Piazza G, Contreras C, Panyam J, Singh A
Curr Mol Med
. 2012 Jul;
12(10):1244-52.
PMID: 22834827
Honokiol (3',5-di-(2-propenyl)-1,1'-biphenyl-2,4'-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol...
4.
Li X, Gao L, Cui Q, Gary B, Dyess D, Taylor W, et al.
Oncogene
. 2012 Jan;
31(48):4979-86.
PMID: 22286762
Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely reported to display strong efficacy for cancer chemoprevention, although their mechanism of action is poorly understood. The most well-documented effects of NSAIDs include...
5.
Li X, Zhang J, Gao L, McClellan S, Finan M, Butler T, et al.
Cell Death Differ
. 2011 Oct;
19(3):378-86.
PMID: 21979467
MicroRNAs (miRNAs) have attracted attention because of their key regulatory functions in many biological events, including differentiation and tumorigenesis. Recent studies have reported the existence of a reciprocal regulatory loop...
6.
Piazza G, Thompson W, Pamukcu R, Alila H, WHITEHEAD C, Liu L, et al.
Cancer Res
. 2001 May;
61(10):3961-8.
PMID: 11358813
Exisulind (Aptosyn) is a novel antineoplastic drug being developed for the prevention and treatment of precancerous and malignant diseases. In colon tumor cells, the drug induces apoptosis by a mechanism...
7.
Lawson K, Ignatenko N, Piazza G, Cui H, Gerner E
Cancer Epidemiol Biomarkers Prev
. 2000 Nov;
9(11):1155-62.
PMID: 11097222
The nonsteroidal anti-inflammatory drug sulindac and the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) are both potent inhibitors of colon carcinogenesis in experimental models of this disease. The combination of these two...
8.
Soh J, Mao Y, Kim M, Pamukcu R, Li H, Piazza G, et al.
Clin Cancer Res
. 2000 Oct;
6(10):4136-41.
PMID: 11051267
Sulindac sulfone (Exisulind) induces apoptosis and exhibits cancer chemopreventive activity, but in contrast to sulindac, it does not inhibit cyclooxygenases 1 or 2. We found that sulindac sulfone and two...
9.
Thompson W, Piazza G, Li H, Liu L, Fetter J, Zhu B, et al.
Cancer Res
. 2000 Jul;
60(13):3338-42.
PMID: 10910034
Sulindac sulfone (exisulind), although a nonsteroidal anti-inflammatory drug derivative, induces apoptosis in tumor cells by a mechanism that does not involve cyclooxygenase inhibition. SW480 colon tumor cells contain guanosine 3',5'-monophosphate...
10.
Lim J, Piazza G, Han E, Delohery T, Li H, Finn T, et al.
Biochem Pharmacol
. 1999 Sep;
58(7):1097-107.
PMID: 10484067
We examined the activity of two metabolites of sulindac (a nonsteroidal anti-inflammatory drug), sulindac sulfide and sulindac sulfone (exisulind, Prevatec), and a novel highly potent analog of exisulind (CP248) on...